ASCENDIS HEALTH LIMITED - Trading statement for the year ended 30 June 2024

Trading statement for the year ended 30 June 2024

Ascendis Health Limited
(Incorporated in the Republic of South Africa)
(Registration number: 2008/005856/06)
Share code: ASC
ISIN: ZAE000185005
("Ascendis" or "the Company")


TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2024


In terms of the Listings Requirements of the JSE Limited, a listed company is required to publish a
trading statement as soon as a reasonable degree of certainty exists that the financial results for the
period to be reported on next will differ by 20% or more from the financial results for the previous
published corresponding period.

It is best practice to adopt a cautious approach in relation to the compilation of quantitative
explanations and considerations for financial results, including a trading statement. Practically and in
terms of the JSE Listings Requirements, this means that issuers are required to provide disclosure of
the forecasts, estimates and judgments by applying IFRS.

This is to ensure that disclosures are:

 *  transparent;
 *  not misleading;
 *  understandable;
 *  reliable;
 *  consistently presented between reporting periods; and
 *  does not obfuscate or detract from the financial information.

Accordingly, the board of directors of Ascendis advises shareholders that it is reasonably certain that
the financial results for the year ended 30 June 2024 ("Current Period"), when compared with the
published results for the year ended 30 June 2023 ("Prior Corresponding Period"), are expected to
differ as follows;


    Continuing Operations        30 June 2023     30 June 2024             30 June 2024
                                 In cents         Expected in cents        Expected
                                                                           (decrease)/increase in %
    Earnings/ (loss) per share   (47.2)           6.0 to 7.3               113% to 115%
    Headline earnings/(loss)     (41.5)           (1.3) to (1.6)           96% to 97%
    per share


    Total Operations             30 June 2023     30 June 2024             30 June 2024
                                 in cents         Expected in cents        Expected
                                                                           (decrease)/increase in %
    Earnings per share           12.4             8.2 to 10.1              (19%) to (34%)
    Headline earnings/(loss)     (39.7)           0.9 to 1.2               102% to 103%
    per share

This trading statement is the responsibility of the directors and the financial information on which this
statement is based has not been reviewed or reported on by the external auditors of the Company.

The expected publication date of the Company's condensed reviewed results is 03 September 2024.

Johannesburg
30 August 2024

Sponsor
Valeo Capital (Pty) Ltd

Date: 30-08-2024 12:25:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.